Navigation Links
Otonomy Completes $45.9 Million Series C Equity Financing
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that it completed a Series C financing which raised $45.9 million in new funds. The investment was led by OrbiMed Advisors, LLC and new investors Aperture Venture Partners and Osage University Partners also participated. Existing investors Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners and TPG Biotech joined in the financing as well. Otonomy plans to use the financing to fund late-stage clinical trials for OTO-201 and OTO-104, development work to advance a third program to clinical trials and general corporate purposes.

(Logo: http://photos.prnewswire.com/prnh/20130806/MM59802LOGO)

The company also announced today that, in conjunction with the financing, Chau Q. Khuong has joined Otonomy's board of directors. Mr. Khuong is private equity partner at OrbiMed and brings significant experience in private company operations as well as business development.

"We are pleased to have some of the world's leading healthcare investors participate in this financing led by OrbiMed," said David A. Weber, Ph.D., president and CEO of Otonomy. "Following the successful completion of clinical trials for both of our product candidates, Otonomy is now positioned to complete late-stage trials for both OTO-104 and OTO-201, and further expand our product pipeline."

"Otic diseases remain underserved by the pharmaceutical industry and represent a significant unmet medical need with millions impacted each year in the U.S. alone," said Mr. Khuong. "OTO-104 and OTO-201 along with the company's proprietary technologies have established Otonomy as a leader in this field, and provide the opportunit
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... 4, 2011 A team of scientists at Tufts ... single-cell levels designed to detect breast cancer earlier, and ... Innovator Award from the Department of Defense Breast Cancer ... Ph.D. The Innovator Awards provide "individuals who ...
...   Research led by St. Jude Children,s Research Hospital scientists ... that are the workhorses of cells and, in the ... The discovery involves a chemical known as ... proteins have this chemical added to the amino acid ...
Cached Medicine Technology:Fighting Breast Cancer Early, One Cell At A Time 2Fighting Breast Cancer Early, One Cell At A Time 3Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:9/18/2014)... September 18, 2014 First Choice ... emergency rooms in the United States, named Douglas J. ... Missouri City-Lakes facility. , “We are pleased to ... medical director of our new Missouri City-Lakes facility,” said ... Choice Emergency Room. , Dr. Harrison received his ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 The Nautilus/ASG ... from active, to medium, and even long term data ... for any length of time. This includes media and ... data. When used together, Nautilus and ASG-Digital Archive will ... content. , "storageFOUNDRY is pleased to work with ...
(Date:9/17/2014)... 2014 The global ablation technologies market ... from 2014 to 2019. Although mature markets (such as ... shares in the ablation technologies market in 2014, the ... CAGR of 12.8% in the next five years.Factors such ... growing number of hospitals and surgical centers, and the ...
(Date:9/17/2014)... 18, 2014 Dr. Shalev is a Texas ... Houston to study at the University of Texas, and graduated ... she realized her real passion lay in dentistry, and she ... the University of Texas Health Science Center at Houston School ... is a member of The Greater Houston Dental Society, and ...
(Date:9/17/2014)... New York, NY (PRWEB) September 18, 2014 ... than 5.9 million tons of medical waste in 2014. ... directly disposed of in landfills along with municipal solid ... the disposal of regulated medical waste (RMW). This includes ... fluids or other potentially infectious materials. As a result ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... Genital herpes caused by a reactivation of herpes simplex ... lesion in one specific area of the genital region. ... frequently reactivate throughout the genital tract, an important new ... prevention. Now available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650302 ), the study ...
... is associated with increased cancer risk. The most ... noted for a common form of liver cancer called ... obesity in mice, researchers at the University of California, ... obesity is tumor-promoting and have obtained evidence that this ...
... Hasbro Children,s Research Center and Hasbro Children,s Hospital researchers ... from The Eunice Kennedy Shriver National Institute of Child ... of asthma on the sleep quality and academic performance ... pediatric researchers, led by Daphne Koinis-Mitchell, PhD, to evaluate ...
... reduce the transmission of influenza-like illness during flu season. ... online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650396 ), published in the Feb. 15 ... In an influenza pandemic, vaccination may not be ... is why scientists need to understand how effective other ...
... The BC Centre for Disease Control has launched ... the pandemic H1N1 flu virus has evolved in British ... months. This project capitalizes on BC,s expertise and ... genomes from circulating influenza viruses collected in British Columbia ...
Cached Medicine News:Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Study shows genital herpes virus reactivates widely throughout genital tract 2Health News:Link between obesity and enhanced cancer risk elucidated 2Health News:New research will examine link between childhood asthma, sleep and school performance 2Health News:Study finds face masks and hand hygiene can help limit influenza's spread 2Health News:Genomic surveillance of pandemic H1N1 2
... Ultracentrifuge power for small-volume samples. With ... method of removing chylomicrons (fat particles in ... results for lipemic clarification. Lipemic samples can ... need for sendouts. The easy-to-operate tabletop ...
... Dimension Xpand integrated chemistry system brings ... to the smaller laboratory. A model ... Xpand integrated chemistry system features state-of-the-art ... low-volume testing environment, in a flexible, ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... Dimension clinical chemistry integrated systems combine the ... cartridge, the power of the Multiply and ... the heterogeneous module to meet the challenges ... broad test menus, the systems can meet ...
Medicine Products: